What the label lists and what reports show
Duloxetine side effects
Duloxetine's FDA label: “Most common adverse reactions (≥5% and at least twice the incidence of placebo-treated patients): (6.1) Adults: nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis Pediatric Patients: nausea, diarrhea, decreased weight To report …” FAERS holds 69,298 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (5,140 reports).
- Generic listed
- Boxed warning
Check it at the source: the duloxetine FDA label on DailyMed (effective May 14, 2024, SUN PHARMACEUTICAL INDUSTRIES, INC.); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of DRIZALMA SPRINKLE?DRIZALMA SPRINKLE may cause serious side effects, including: •See, “What is the most important information I should know about DRIZALMA SPRINKLE?” • Liver problems. DRIZALMA SPRINKLE may cause severe liver problems that may cause death. Tell your healthcare provider right away if you develop any of the following symptoms of severe liver problems:• Decreased in blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position, especially when you start or restart treatment or when the dose is changed.• Falls and fainting. DRIZALMA SPRINKLE may cause you to feel sleepy or dizzy, may cause a decrease in your blood pressure when you rise to quickly from a sitting or lying position, and can slow your thinking and motor skills which may lead to falls that have caused fractures or other serious injuries.• Serotonin syndrome. […]
Source: FDA drug label, SUN PHARMACEUTICAL INDUSTRIES, INC., effective May 14, 2024 (SPL set b41423b8-dfec-4d79-ba3c-e43a87803d85), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (≥5% and at least twice the incidence of placebo-treated patients): (6.1) Adults: nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis Pediatric Patients: nausea, diarrhea, decreased weight To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc.
Table 3: Adverse Reactions: Incidence of 2% or More and Greater than Placebo in MDD and GAD Placebo-Controlled Trials in Adults a,b
This table is printed in the Duloxetine label published by Almatica Pharma LLC of March 2, 2026; the label quoted above does not print one.
| Reaction | System Organ Class / Adverse Reaction Another Duloxetine Product (N=4797) | Percentage of Patients Reporting Reaction Placebo (N=3303) |
|---|---|---|
| Cardiac Disorders Palpitations | 2 | 1 |
| Eye Disorders Vision blurred | 3 | 1 |
| Nausea c | 23 | 8 |
| Dry mouth | 14 | 6 |
| Constipation c | 9 | 4 |
| Diarrhea | 9 | 6 |
| Abdominal pain d | 5 | 4 |
| Vomiting | 4 | 2 |
| General Disorders and Administration Site Conditions Fatigue e | 9 | 5 |
| Metabolism and Nutrition Disorders Decreased appetite c | 6 | 2 |
| Headache | 14 | 14 |
| Dizziness c | 9 | 5 |
| Somnolence f | 9 | 3 |
| Tremor | 3 | 1 |
| Insomnia g | 9 | 5 |
| Agitation h | 4 | 2 |
| Anxiety | 3 | 2 |
| Erectile dysfunction | 4 | 1 |
| Ejaculation delayed c | 2 | 1 |
| Libido decreased i | 3 | 1 |
| Orgasm abnormal j | 2 | <1 |
| Respiratory, Thoracic, and Mediastinal Disorders Yawning | 2 | <1 |
| Skin and Subcutaneous Tissue Disorders Hyperhidrosis | 6 | 2 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following adverse reactions are discussed in more detail in other sections of the labeling: Suicidal Thoughts and Behaviors in Adolescents and Young Adults [see Boxed Warning and Warnings and Precautions (5.1)] Hepatotoxicity [see Warnings and Precautions (5.2)] Orthostatic Hypotension, Falls and Syncope [see Warnings and Precautions (5.3)] Serotonin Syndrome [see Warnings and Precautions (5.4)] Increased Risk of Bleeding [see Warnings and Precautions (5.5)] Severe Skin Reactions [see Warnings and Precautions (5.6)] Discontinuation Syndrome [see Warnings and Precautions (5.7)] Activation of Mania/Hypomania [see Warnings and Precautions (5.8)] Angle-Closure Glaucoma [see Warnings and Precautions (5.9)] Seizures [see Warnings and Precautions (5.10)] Increases in Blood Pressure [see Warnings and Precautions (5.11)] Clinically Important Drug Interactions [see Warnings and Precautions (5.12)] Hyponatremia [see Warnings and Precautions (5.13)] Urinary Hesitation and Retention [see Warnings and Precautions (5.15)] Sexual Dysfunction [see Warnings and Precautions (5.16)] Most common adverse reactions (≥5% and at least twice the incidence of placebo-treated patients): (6.1) Adults: nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis Pediatric Patients: nausea, diarrhea, decreased weight To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical …
Source: FDA drug label, SUN PHARMACEUTICAL INDUSTRIES, INC., effective May 14, 2024 (SPL set b41423b8-dfec-4d79-ba3c-e43a87803d85), via openFDA; the full label on DailyMed
What do FAERS reports show?
69,298 reports list duloxetine among the medicines taken, each a report of something that happened, not proof the medicine caused it; 7,118 are coded as a death and 22,135 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 16 reactions below, 11 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Duloxetine: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions